Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.49 |
| ▸ | RARG | P13631 | 4/20 | 0.49 |
| ▸ | RARA | P10276 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | VDR | P11473 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4759945 | 1.00 | RARB (0.49) | RARBRARGRARAPTPN1VDR | |
| SCHEMBL4760481 | 0.85 | PTPN1 (0.41) | RARBRARGRARAPTPN1VDR | |
| SCHEMBL4760479 | 0.85 | PTPN1 (0.41) | RARBRARGRARAPTPN1VDR | |
| SCHEMBL14159838 | 0.82 | RARB (0.49) | RARBRARGRARAPTPN1VDR | |
| SCHEMBL14159916 | 0.82 | RARB (0.49) | RARBRARGRARAPTPN1VDR | |
| SCHEMBL14159976 | 0.81 | RARB (0.57) | RARBRARGRARAPTPN1VDR | |
| SCHEMBL10844563 | 0.80 | RARB (0.64) | RARBRARGRARAPTPN1VDR | |
| SCHEMBL4666958 | 0.80 | RARB (0.75) | RARBRARGRARAPTPN1VDR | |
| SCHEMBL10844561 | 0.80 | RARB (0.64) | RARBRARGRARAPTPN1VDR | |
| SCHEMBL2594345 | 0.80 | RARB (0.75) | RARBRARGRARAPTPN1VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935869-A1 | Retinoids for the treatment of emphysema | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| US-6777418-B2 | FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-08-17 | — | — | US | disclosed |
| EP-1324970-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | SYNTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
| WO-2002028810-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | RXRA, RXRG, RXRB | RARB 6/4885RARG 4/4885RARA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.